Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial.

@article{Hermsen2007GlutamaterichP,
  title={Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial.},
  author={Cornelus Hermsen and Danielle F Verhage and Denise S C Telgt and Karina Teelen and J Teun Bousema and Meta Roestenberg and Ahmed Bolad and Klavs Berzins and Giampietro Corradin and Odile Leroy and Michael J. Theisen and Robert W. Sauerwein},
  journal={Vaccine},
  year={2007},
  volume={25 15},
  pages={
          2930-40
        }
}
The glutamate-rich protein (GLURP) of P. falciparum is the target of cytophilic antibodies which are significantly associated with protection against clinical malaria. A phase 1 clinical trial was conducted in healthy adult volunteers with the long synthetic peptide (LSP) GLURP(85-213) combined with either Aluminum Hydroxide (Alum, 18 volunteers) or Montanide ISA 720 (ISA, 18 volunteers) as adjuvants. Immunizations with 10, 30 or 100 microg GLURP(85-213) were administered subcutaneously at days… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 57 CITATIONS, ESTIMATED 72% COVERAGE

Progress and prospects for blood-stage malaria vaccines

  • Expert review of vaccines
  • 2016
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2006
2019

CITATION STATISTICS

  • 3 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 28 REFERENCES

clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA 720 adjuvant

F Nosten, C Luxemburger, DE Kyle
  • 2005

trial of Pvs 25 H : a transmission blocking vaccine for Plasmodium vivax malaria

A Saul, G Lawrence, A Smillie
  • 2005

( PfCS - MAP 1 NYU ) against Plasmodium falciparum sporozoites

WA Keitel, KE Kester, RL Atmar
  • 2002